TL1A blockade in inflammatory bowel diseases: Clinical trials to watch.

Date publication

décembre 2025

Journal

Med (New York, N.Y.)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
D'Amico F, Peyrin-Biroulet L, Jairath V, Danese S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41389712

Résumé

TL1A inhibitors offer a novel therapeutic strategy in inflammatory bowel disease by combining anti-inflammatory effects with potential antifibrotic activity. Phase 2 studies show clinical efficacy and a favorable safety profile. Ongoing phase 3 trials will further define their role, including the utility of genetic predictors to guide patient-specific therapy.

Mots clés

Humans, Inflammatory Bowel Diseases, drug therapy, Tumor Necrosis Factor Ligand Superfamily Member 15, antagonists & inhibitors, Clinical Trials as Topic, Anti-Inflammatory Agents, therapeutic use, Antibodies, Monoclonal, Humanized, therapeutic use

Référence

Med. 2025 12 12;6(12):100931